http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
-
Ionis to present at upcoming investor conferences
-
Ionis updates time for fourth quarter and full year 2025 financial results webcast
-
Ionis to hold fourth quarter and full year 2025 financial results webcast
-
DAWNZERA gets European Commission approval for hereditary angioedema
-
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
-
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
-
GSK hepatitis B drug meets goals in phase 3 trials
-
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
-
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
-
Ionis receives FDA breakthrough therapy designation for Alexander disease drug
-
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
-
Ionis receives FDA breakthrough therapy status for severe hypertriglyceridemia drug
-
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
-
Ionis' DAWNZERA receives EU regulatory committee recommendation for HAE
-
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
-
Ionis to present at upcoming investor conferences
-
Ionis reports olezarsen cut triglyceride levels up to 72% in pivotal trials
-
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
-
Ionis presents long-term DAWNZERA data at ACAAI meeting
-
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
-
Ionis reports third quarter 2025 financial results and highlights progress on key programs
-
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
-
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
-
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
-
Ionis to hold third quarter 2025 financial results webcast
-
Ionis hosts innovation day, targets sustained cash flow by 2028
-
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
-
Ionis reports positive results for Alexander disease drug zilganersen
-
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
-
TRYNGOLZA approved in Europe for rare genetic syndrome FCS
-
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
-
Ionis expands adaptive event for neurological disease communities
-
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
-
Ionis receives FDA breakthrough therapy designation for ION582
-
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
-
Ionis to host investors and analysts for Innovation Day 2025
-
Ionis to present at upcoming investor conferences
-
Ionis olezarsen shows 72% triglyceride reduction in Phase 3 studies
-
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
-
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
-
Ionis reports second quarter 2025 financial results and highlights progress on key programs
-
Ionis drug TRYNGOLZA gets EU committee approval recommendation for rare disease
-
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
-
Ionis reports positive HAE treatment switch study results
-
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
-
Ionis to hold second quarter 2025 financial results webcast
-
Ionis Pharmaceuticals (IONS) announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
-
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
-
Ionis Pharmaceuticals (IONS) Announces Retirement of Chief Development Officer
